Bridging the early-stage funding gap to fuel breakthroughs in autoimmune treatments and speed the path from discovery to life-changing cures.
Progress in autoimmune research requires access to risk-tolerant early capital, which today is limited. IBC will partner with founders to generate decisive data, unlock follow-on funding, and speed therapies and diagnostics forward in commercial development to provide tomorrow’s innovative treatments.
We welcome outreach from emerging companies as well as academic spinouts. Share a concise non-confidential overview (problem, solution, evidence, development plan, financing requirements and timeline to first milestone) and we’ll follow up.
